Compare INVZ & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVZ | IVA |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | Israel | France |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.5M | 1.1B |
| IPO Year | 2020 | 2020 |
| Metric | INVZ | IVA |
|---|---|---|
| Price | $0.34 | $4.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $2.68 | ★ $16.20 |
| AVG Volume (30 Days) | ★ 5.0M | 671.3K |
| Earning Date | 05-14-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.61 | N/A |
| Revenue Next Year | $53.57 | $751.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $3.35 |
| 52 Week High | $2.54 | $7.98 |
| Indicator | INVZ | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 30.45 | 57.98 |
| Support Level | N/A | $4.46 |
| Resistance Level | $0.47 | $4.94 |
| Average True Range (ATR) | 0.02 | 0.15 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 18.84 | 65.31 |
Innoviz Technologies Ltd is a provider of LiDAR technology, serving as a Tier 1 supplier to the world's automotive manufacturers. Its LiDAR and perception software "see" further than a human driver and reduce the possibility of error, meeting the automotive industry's strictest expectations for performance and safety. Its sensors are designed to deliver exceptional range, resolution, and reliability, providing accurate 3D sensing in harsh weather conditions. Operating across the U.S., Europe, and Asia. Innoviz designs solutions for automotive OEMs, system integrators, municipalities, commercial enterprises, and others. InnovizSMART is an off-the-shelf solution for security, defense, and homeland security, intelligent traffic management, mobility, robotics, and aerial applications.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.